BioNeutra™

BIONEUTRA GLOBAL CORPORATION - A CANADIAN AWARDS LEADER – ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

Edmonton, Alberta – (May 1, 2020) – BioNeutra Global Corporation ("BioNeutra" or the "Company") (TSXV: BGA) is pleased to announce the appointment of Mr. Branko Jankovic as Chief Financial Officer effective today. Mr. Jankovic will lead the Company's global financial strategy and oversee the Company's financial operations.

Mr. Jankovic is a Chartered Professional Accountant and Chartered Accountant. He has extensive financial and accounting leadership experience in both public and private companies operating in both Canada and the U.S. His experience includes roles with three publicly traded life sciences companies including serving as CFO for one for nine years. In 2019 he served on BioNeutra's Board of Directors and chaired its audit committee. Mr. Jankovic has deep roots in the functional food sector and spent three years with the Agriculture & Food Council of Alberta.

BioNeutra President and CEO, Dr. Jianhua Zhu, says, "BioNeutra is extremely fortunate to have Branko join our Company. His diverse public company experience and sector experience with be a great asset to BioNeutra."

Mr. Jankovic says, "This is a great company with talented people. I expect a quick transition into this role as I recently chaired the audit committee and look forward to providing expert leadership for BioNeutra and its continued growth."

Mr. Jankovic received his Bachelor of Commerce degree from Lakehead University where he was awarded the Dean's Medal for top standing.

About BioNeutra

BioNeutra is an award-winning, sector-leading Canadian company in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages, with a focus on VitaFiber™IMO.

The Company's lead product, VitaFiber™IMO, is an advanced functional and health food and beverage ingredient scientifically made from natural agricultural products, is generally regarded as safe (GRAS) by the U.S. Food & Drug Administration and is European Food Safety Authority and Health Canada approved as a novel food ingredient. VitaFiber™IMO is naturally sweet and lower in calories than sugar and is a natural source of dietary fiber as it provides low calorie soluble prebiotic fiber for human digestive health.

The VitaFiber™ IMO manufacturing process is based upon a natural enzymatic conversion of starch molecules without any chemical modification involved, making VitaFiber™IMO a natural food and beverage ingredient. VitaFiber™IMO is also non-GMO, vegan-friendly, gluten-free, Kosher and Halal certified and available as certified organic.

The Company's customers include a mix of small and medium enterprises and a number of high-profile food and beverage manufacturers in Canada, the U.S., Europe and the United Kingdom. VitaFiber™IMO is also available for retail purchase across the globe through Amazon.com and other direct-to-consumer retailers.

Further information about BioNeutra is available on the Company's website at www.bioneutra.ca and the SEDAR website at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information on BioNeutra, please contact:

Dr. Jianhua Zhu
President and Chief Executive Officer
Tel: (780) 466-1481 (Ext. 132)
Email: jianhua.zhu@bioneutra.ca

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.